Acrux
Manufacturing · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
103-113 Stanley St, West Melbourne, Vict...Phone Number
+61 383790100Website
www.acrux.com.auRevenue
<$5 MillionStock Symbol
ACRIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Acrux
Acrux is a specialty pharmaceutical company that develops and commercialises topical and transdermal prescription medicines for global healthcare markets. The company focuses on creating generic and branded drug delivery systems such as sprays, gels, creams, and solutions that improve patient convenience and treatment effectiveness. It works with international partners to bring regulated pharmaceutical products to market, leveraging in-house formulation, development, and manufacturing capabilities for skin-applied therapies.Explore more
Acrux Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Acrux your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Acrux has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Acrux
Acrux, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Acrux recently announced quarterly report
Funding: Get notified immidiatlly once Acrux has new funding data
Product Launch: Get notified when Acrux launches new products
Check out if Acrux is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Acrux had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Acrux as Masked Content
Find 2 more new buyers
Compare Similar Companies to Acrux
Compare insights from companies similar to Acrux, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Acrux is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Acrux is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Acrux.
Acrux financials insights
Gather financial insights about Acrux, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Stock/Share Issuance
$1.6M
Acrux Tech Stack
A closer look at the technologies used by Acrux
Most Recent Scoops
Funding
Funding
Award
Acrux has been granted a new patent by the Indian Patent Office for its DNA polymerase IIIC inhibitors, expiring in December 2039, subject to extension. This patent supports the company's preclinical antibiotic development program for ACX-375C, targeting infections caused by MRSA, VRE, DRSP, and anthrax.
Research & Development, Intellectual Property, Legal Affairs, Pharmaceuticals
Product Launch
Acrux has announced the publication of its phase IIb clinical trial data for ibezapolstat and C. difficile infection in The Lancet Microbe. The publication highlighted high rates of clinical cure with no recurrence, safety, and preservation of key health-promoting bacteria responsible for bile acid homeostasis.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Acrux has reported that ibezapolstat clinical results continue to demonstrate leadership in treating C. difficile infection, which the U.S. CDC categorizes as an urgent threat.
Medical Research, Pharmaceuticals, Business Finance, Finance
Funding
Business Finance, Finance, Financing & Debt
Acrux News & Media
Australian company unlocks a new era for women's health globally with an innovative delivery system for Female testosterone in women with low libido
Massive unmet need for Hypoactive Sexual Desire Disorder treatments addressed by new Female Testosterone product Phase I and II clinical trials completed. Phase III to be done in co-development with global partners. Unique, Australian developed unique Patchless Patch™ delivery technology MELBOURNE, Australia, April 28, 2026 /PRNewswire/ -- Acrux is a successful Australian pharmaceutical company that develops innovative drugs for the global market. It recently announced its new strategy to enterAcrux Limited's (ASX:ACR) CEO Will Probably Find It Hard To See A Huge Raise This Year
Key Insights Acrux will host its Annual General Meeting on 28th of November Salary of AU$462.7k is part of CEO Michael...Transdermal Drug Delivery Devices Market Outlook 2027 | Mylan, GlaxoSmithKline, Acrux Limited
Transdermal Drug Delivery Devices Market Outlook 2027 Mylan GlaxoSmithKline Acrux LimitedAcrux (ASX:ACR) pushes ahead with $2M SPP
Acrux (ASX:ACR) is pushing ahead with its $2 million share purchase plan (SPP) by sending off a booklet to shareholders.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Acrux
Sign Up For FreeTo access detailed company insights
Acrux is a specialty pharmaceutical company that develops and commercialises topical and transdermal prescription medicines for global healthcare markets. The company focuses on creating generic and branded drug delivery systems such as sprays, gels, creams, and solutions that improve patient convenience and treatment effectiveness. It works with i... Read More
